{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"23.1","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Time to Response was calculated as the time from enrollment to the initial response (PR or better) based on IMWG and assessed by the investigator.","dispersionType":"Full Range","groups":[{"description":"Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity","id":"OG000","title":"Pomalidomide"}],"paramType":"MEDIAN","populationDescription":"Includes those who had at least a partial response or better; Intent to Treat","reportingStatus":"POSTED","timeFrame":"From randomization through the follow-up phase; up to the data-cut off of 31 July 2014; Maximum time to response was 23.1 weeks","title":"Time to Response Based on IMWG and Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"weeks"}